{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:38:08Z","timestamp":1792539488192,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA209-731"],"award-info":[{"award-number":["CA209-731"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012231","name":"Society of Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmogo.2026.100402","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:48:28Z","timestamp":1786992508000},"page":"100402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-4310","authenticated-orcid":false,"given":"J.J.","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.M.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yarmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-0310","authenticated-orcid":false,"given":"R.K.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-849X","authenticated-orcid":false,"given":"P.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.N.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"El Dika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yaqubie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7479-1277","authenticated-orcid":false,"given":"J.D.","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Nadolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-8468","authenticated-orcid":false,"given":"A.","family":"Covey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-727X","authenticated-orcid":false,"given":"J.P.","family":"Erinjeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-0037","authenticated-orcid":false,"given":"K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Soulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Capanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.K.","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmogo.2026.100402_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100402_bib2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100402_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100402_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10492","key":"10.1016\/j.esmogo.2026.100402_bib5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100402_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100402_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.esmogo.2026.100402_bib8","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100402_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100402_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cyto.2013.07.021","article-title":"Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma","volume":"64","author":"Kim","year":"2013","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100402_bib11","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1038\/s41598-019-40078-8","article-title":"Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100402_bib12","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4049\/jimmunol.178.3.1914","article-title":"Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization","volume":"178","author":"Ayaru","year":"2007","journal-title":"J Immunol"},{"issue":"18","key":"10.1016\/j.esmogo.2026.100402_bib13","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4254\/wjh.v9.i18.808","article-title":"Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma","volume":"9","author":"Song","year":"2017","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100402_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100402_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100402_bib16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100402_bib17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"issue":"10088","key":"10.1016\/j.esmogo.2026.100402_bib18","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100402_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.annonc.2023.12.008","article-title":"Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040","volume":"35","author":"El-Khoueiry","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100402_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"282","key":"10.1016\/j.esmogo.2026.100402_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100402_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann Math Statist"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100402_bib23","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-24-0177","article-title":"Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study","volume":"30","author":"Pinato","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"suppl 4","key":"10.1016\/j.esmogo.2026.100402_bib24","article-title":"Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis","volume":"43","author":"Heo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100402_bib25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/cancers16081498","article-title":"Retrospective long-term evaluation of conventional transarterial chemoembolization for hepatocellular carcinoma over 20 years","volume":"16","author":"Vogl","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2026.100402_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1072922","article-title":"Transarterial chemoembolization for advanced hepatocellular carcinoma without macrovascular invasion or extrahepatic metastasis: analysis of factors prognostic of clinical outcomes","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"},{"issue":"10474","key":"10.1016\/j.esmogo.2026.100402_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.esmogo.2026.100402_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"suppl 62","key":"10.1016\/j.esmogo.2026.100402_bib29","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100402_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO-25-01796","article-title":"Transarterial chemoembolization combined with camrelizumab and rivoceranib for unresectable hepatocellular carcinoma (CHANCE2005\/CARES-005): a randomized phase II trial","volume":"44","author":"Zhu","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmogo.2026.100402_bib32","article-title":"A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC)","volume":"39","author":"Sangro","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100402_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jvir.2023.10.033","article-title":"Synergizing thermal ablation modalities with immunotherapy: enough to induce systemic antitumoral immunity?","volume":"35","author":"Mustafa","year":"2024","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100402_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/cancers16050855","article-title":"Thermal ablation combined with immune checkpoint blockers: a 10-year monocentric experience","volume":"16","author":"Bonnet","year":"2024","journal-title":"Cancers"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:37:58Z","timestamp":1792535878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S2949819826001020"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100402","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100402"}}